Eosinophilic vasculitis in connective tissue disease.
BACKGROUND
Neutrophilic and lymphocytic vascular inflammation is common in vasculitis associated with connective tissue disease (CTD). We recently identified eight patients with CTD and eosinophilic vasculitis.


OBJECTIVE
The purpose of this study was to characterize a variant form of vasculitis in CTD with eosinophilic infiltration.


METHODS
Of 98 CTD patients with cutaneous necrotizing vasculitis, eight were found with predominantly eosinophilic vascular infiltration. Nine CTD patients with cutaneous neutrophilic vasculitis were identified for comparison. Clinical and laboratory findings were reviewed and compared. Indirect immunofluorescence for eosinophil granule major basic protein (MBP), neutrophil elastase, and mast cell tryptase was performed on lesional tissue. MBP levels and eosinophil survival enhancing activity were assayed in sera from three patients.


RESULTS
The patients with eosinophilic vasculitis had depressed serum complement levels and peripheral blood eosinophilia; MBP levels were elevated in serum and eosinophil survival was prolonged. Immunofluorescence of tissue showed marked angiocentric eosinophil MBP staining with peripheral neutrophil elastase staining; mast cell tryptase staining was notably absent. The patients with neutrophilic vasculitis were variably hypocomplementemic and did not have peripheral blood eosinophilia. Immunofluorescence showed marked angiocentric neutrophil elastase staining with scattered eosinophil MBP staining; mast cell tryptase staining showed normal mast cell numbers.


CONCLUSIONS
Patients with eosinophilic vasculitis, CTD, and hypocomplementemia show vessel wall destruction in association with vessel wall deposition of cytotoxic eosinophil granule MBP, which suggests that eosinophils mediate vascular damage in this disease process. In addition, perivascular mast cells appear diminished, thereby suggesting that mast cell degranulation occurs.
Chen
K R
KR
Department of Dermatology, Mayo Clinic, Rochester, MN 55905, USA.
Su
W P
WP
Pittelkow
M R
MR
Conn
D L
DL
George
T
T
Leiferman
K M
KM
D000328:Adult; D001798:Blood Proteins / Q000032:analysis; D015550:Cell Degranulation; D002470:Cell Survival; D053818:Chymases; D003165:Complement System Proteins / Q000032:analysis; D003240:Connective Tissue Diseases / Q000150:complications* / Q000473:pathology; D047091:Eosinophil Granule Proteins; D004802:Eosinophilia / Q000150:complications* / Q000473:pathology; D004804:Eosinophils / Q000473:pathology; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D018836:Inflammation Mediators / Q000032:analysis; D019272:Leukocyte Elastase; D008214:Lymphocytes / Q000473:pathology; D008297:Male; D008407:Mast Cells / Q000473:pathology; D008875:Middle Aged; D009504:Neutrophils / Q000473:pathology; D010196:Pancreatic Elastase / Q000032:analysis; D012260:Ribonucleases; D012697:Serine Endopeptidases / Q000032:analysis; D017445:Skin Diseases, Vascular / Q000150:complications* / Q000473:pathology; D053802:Tryptases; D014657:Vasculitis / Q000150:complications* / Q000473:pathology
D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D018836:Inflammation Mediators; D003165:Complement System Proteins; D012260:Ribonucleases; D012697:Serine Endopeptidases; C083294:chymase 2; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase; D053818:Chymases; D053802:Tryptases